Lilly says diabetes drug Trulicity reduces heart risks in trial
Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes, according to results of a large clinical trial.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cardiology | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Health | Heart | Heart Attack | Stroke